Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
VERAXA Biotech has moved into additional laboratory space at its R&D site in Heidelberg, Germany, based on a previously signed long-term lease agreement.
-
VERAXA Biotech AG (NASDAQ: VRXA) has generated new in vitro proof-of-concept data validating its novel BiTAC-ADC technology platform.
-
The business combination of VERAXA Biotech and Voyager Acquisition Corp. was closed successfully and NASDAQ trading of $VRXA commences on June 11, 2026.
-
Ona Therapeutics closes oversubscribed $86.6M Series B financing to advance first-in-class ADCs into clinical development for treatment-resistant cancers
-
Global experts in antibody-drug conjugate (ADC) development, oncology clinical development and early-phase trial design, appointed to support advancement of Byondis’ differentiated ADC pipeline and a...
-
Global experts in antibody-drug conjugate (ADC) development, oncology clinical development and early-phase trial design, appointed to support advancement of Byondis’ differentiated ADC pipeline and a...
-
Tacalyx Secures €11 Million to Advance Lead TACA-Targeting ADC Programme Toward the Clinic Berlin, Germany, April 29, 2026 (GLOBE NEWSWIRE) -- Tacalyx, a leader in the discovery and development of...
-
Presentations highlight therapy-induced senescence as a new opportunity and reinforce STX-1’s potential as a differentiated approach in solid tumors.
-
SAN DIEGO, March 24, 2026 (GLOBE NEWSWIRE) -- VivoSim Labs, Inc. (Nasdaq: VIVS) (the “Company” or “VivoSim”), a provider of next-generation New Approach Methodologies (NAMs) for preclinical safety,...
-
VERAXA shareholders approve merger & issuance of new shares to Voyager. Both resolutions are prerequisites for the closing of the business combination.